ATNX - Axis Therapeutics inks research pact with PharmaEssentia for cancer T-cell therapy

Axis Therapeutics, a joint venture between Athenex (ATNX) and Xiangxue Life Sciences has entered into a research collaboration with PharmaEssentia for development of T Cell Receptor ((TCR))-T therapy in Taiwan.Under the terms of the agreement, Axis Therapeutics and PharmaEssentia will collaborate to conduct an initial clinical study of former's TCRT-ESO-A2 therapy, targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients, and to manufacture the investigational products, in Taiwan.PharmaEssentia will be responsible for clinical development in Taiwan.Athenex recently announced that the FDA has signed-off an Investigational New Drug application for this same compound.

For further details see:

Axis Therapeutics inks research pact with PharmaEssentia for cancer T-cell therapy